Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Tharimmune Inc
THAR
Healthcare
Biotechnology
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active...
compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:THAR)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 18, 2024 8:02am
New Press Release - Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse eventsPhase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 13, 2024 8:01am
New Press Release - Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 04, 2024 9:01am
New Press Release - Tharimmune Announces Upcoming Conference Presentations
BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 30, 2024 2:06pm
THAR....Now take a wild guess where it is!!!!!
Yep....... New N.L.O.D Now at $3.68.....U hearing me ????
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Oct 30, 2024 1:52pm
RE:THAR..... JUst tapped the N.L.O.D at $4.07
You might try re-reading all my posts on this board ! I find it quite hilarious that I get absolutely ZERO likes....I guess I'm just talking to myself ; ) Cheers !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 30, 2024 1:44pm
THAR.... start the drumroll...just tapped the New
N.L.O.D...........$4
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 30, 2024 11:31am
THAR..... JUst tapped the N.L.O.D at $4.07
Declining volume and the sh price trend is not your friend Next support is ........ $3.58 No position since the opening bell ; )
(274)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Oct 30, 2024 10:00am
Tharimmune Receives Positive Regulatory Feedback From EMA fo
Just In: $THAR Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary CholangitisBRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 /
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 30, 2024 9:42am
THAR....in hindsight
I sold too early...mind you it trade sub $5 after I sold. I really don't give a sheet where it goes now....moving on to the next one Cheers !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 30, 2024 9:39am
THAR....Halt #1
Last at $6.28
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 30, 2024 9:33am
THAR.....sold all into the opening strength !!!!
Cha F'king Ching !!!!!!!!!!!!!!!!!!!!!
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Oct 30, 2024 8:46am
RE:THAR....all-time low at $2
Just re-posting what I told you almost a month ago .....Is it wortha repeat? "Hell ya" !!!!!!!!!!!!!!!
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Oct 30, 2024 8:33am
RE:THAR....News released
https://www.youtube.com/watch?v=GpAUDOI24Oo
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 30, 2024 8:20am
THAR......Thar she blows !!!!!!!!!
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis 2024-10-30 05:16 ET - News Release BRIDGEWATER, NJ
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 30, 2024 8:16am
New Press Release - Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback from a Scientific Advice meeting...
read article.
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth